首页 | 本学科首页   官方微博 | 高级检索  
   检索      


On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY
Authors:Seebach Dieter  Lukaszuk Aneta  Patora-Komisarska Krystyna  Podwysocka Dominika  Gardiner James  Ebert Marc-Olivier  Reubi Jean Claude  Cescato Renzo  Waser Beatrice  Gmeiner Peter  Hübner Harald  Rougeot Catherine
Institution:1. Laboratorium für Organische Chemie, Departement für Chemie und Angewandte Biowissenschaften, ETH‐Zürich, H?nggerberg, Wolfgang‐Pauli‐Strasse 10, CH‐8093 Zürich, (phone: +41‐44‐632‐2990;2. fax: +41‐44‐632‐1144);3. Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, P.?O. Box 62, CH‐3010 Bern (phone: +41?31?632?3242;4. fax: +41?31?632?8999);5. Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich Alexander University, Schuhstra?e 19, D‐91052 Erlangen (phone: +49?9131?8529383;6. fax: +49?9131?8522585);7. Institut Pasteur – Unité de Biochimie Structurale et Cellulaire/URA2185 – CNRS, 25 rue du Docteur Roux, F‐75724 Paris (phone: +33?1?4061?3445;8. fax: +33?1?45?68?8399)
Abstract:The terminal homologation by CH2 insertion into the peptides mentioned in the title is described. This involves replacement of the N‐terminal amino acid residue by a β2‐ and of the C‐terminal amino acid residue by a β3‐homo‐amino acid moiety (β2hXaa and β3hXaa, resp.; Fig. 1). In this way, the structure of the peptide chain from the N‐terminal to the C‐terminal stereogenic center is identical, and the modified peptide is protected against cleavage by exopeptidases (Figs. 2 and 3). Neurotensin (NT; 1 ) and its C‐terminal fragment NT(8–13) are ligands of the G‐protein‐coupled receptors (GPCR) NT1, NT2, NT3, and NT analogs are promising tools to be used in cancer diagnostics and therapy. The affinities of homologated NT analogs, 2b – 2e , for NT1 and NT2 receptors were determined by using cell homogenates and tumor tissues (Table 1); in the latter experiments, the affinities for the NT1 receptor are more or less the same as those of NT (0.5–1.3 vs. 0.6 nM ). At the same time, one of the homologated NT analogs, 2c , survives in human plasma for 7 days at 37° (Fig. 6). An NMR analysis of NT(8–13) (Tables 2 and 4, and Fig. 8) reveals that this N‐terminal NT fragment folds to a turn in CD3OH. – In the case of the human analgesic opiorphin ( 3a ), a pentapeptide, and of the HIV‐derived B27‐KK10 ( 4a ), a decapeptide, terminal homologation (→ 3b and 4b , resp.) led to a 7‐ and 70‐fold half‐life increase in plasma (Fig. 9). With N‐terminally homologated NPY, 5c , we were not able to determine serum stability; the peptide consisting of 36 amino acid residues is subject to cleavage by endopetidases. Three of the homologated compounds, 2b, 2c , and 5c , were shown to be agonists (Fig. 7 and 11). A comparison of terminal homologation with other stability‐increasing terminal modifications of peptides is performed (Fig. 5), and possible applications of the neurotensin analogs, described herein, are discussed.
Keywords:Peptides  Peptidomimetics  Terminal homologation  Neurotensin  Opiorphin  B27‐KK10 Epitope  NPY  Endopetidases  Exopeptidases  β‐Peptides
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号